| 生物活性 |
Sorafenib (Bay 43-9006) is a potent, orally active multi-kinase (tyrosine kinases) inhibitor that blocks the autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby inhibiting the RAF/MEK/ERK and PI3K/Akt pathways and STAT3 phosphorylation, and induces cell cycle arrest, autophagy and apoptosis as well as PARP cleavage, decreases Bcl-2, Bcl-XL and cyclin D1 protein levels, and activates Bak and Bax, thus inhibiting tumor growth and metastasis in mouse and rat models; it can be used in cancer research, such as studies on colon cancer, breast cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, melanoma, colorectal cancer and hepatocellular carcinoma. |
| IC50 & Target |
B-CPAP cells:1.85 µM, Flt3:58 nM, VEGFR3:20 nM (cell free), BHT-101 cells:2.1 µM, Raf-1:6 nM (cell free), Huh7 cells:5.97 μM, HepG2 cells:7.42 μM, B-Raf V599E:38 nM (cell free), Hep b3B cells:3.31 μM, TPC1 cells:2.6 µM, c-Kit:68 nM (cell free), VEGFR2:90 nM, PDGFRβ:57 nM (cell free), B-Raf:22 nM (cell free), FTC133 cells:2.9 µM |
体外研究 (In Vitro) |
Sorafenib (0.01-3 μM; 2 h) 在 MDA-MB-231 细胞中选择性抑制 MAPK 通路,而对 PKB 通路没有影响。
Sorafenib (0.01-3 μM; 2 h) 可抑制 MDA-MB-231 人乳腺癌细胞中 MEK 1/2 和 ERK 1/2 的磷酸化 (IC50 分别为 40 nmol/L 和 90 nmol/L),还可抑制 BxPC-3、LOX、HCT 116、HT-29、Colo-205 及 Mia PaCa-2 细胞中 ERK 1/2 的磷酸化,但对 A549 和 NCI-H460 人非小细胞肺癌细胞中 ERK 1/2 的磷酸化无抑制作用。
Sorafenib (0.01-10 μM; 72 h) 可抑制 MDA-MB-231 细胞的增殖,IC50 为 2600 nmol/L。 Sorafenib (8.9 μM) 在人结直肠癌 HCT8 和 HT29 细胞系中的 IC50 为 8.9 μM,且在所有测试孵育方案中均与奥沙利铂和顺铂表现出显著拮抗作用,可降低铂类诱导的细胞毒性。
Sorafenib (4-24 μM; 24 h) 与 Oxaliplatin (MS-L84463) 或 Cisplatin (MS-E94993) 共同孵育时,可降低 HCT8 和 HT29 细胞中 p21Cip1 和 cyclin D1 蛋白的表达。
Sorafenib (24 μM; 4 h) 同时应用时可显著降低 HCT8 和 HT29 细胞中 Cisplatin 和 Oxaliplatin 诱导的 DNA 加合物水平,但在连续应用时则不会影响加合物水平或修复过程。
Sorafenib (0-20 μmol/L; 24-72 h) 可呈时间和剂量依赖性抑制 HCCLM3、HepG2 和大鼠 Morris 3924A (MH) 肝癌细胞系的增殖。
Sorafenib (0-20 μmol/L; 2-24 h) 可在 HCCLM3、HepG2 和 MH 肝癌细胞系中持久抑制 STAT3Y705、STAT3S727、ERK1/2 及 Akt 的磷酸化,并降低 cyclin D1 的表达,且不会改变 JAK2 或 SHP2 的磷酸化水平。
Sorafenib (5 μM; 48 h) 可显著提高 A549、NCI-H460 和 NCI-H1299 非小细胞肺癌 (NSCLC) 细胞的克隆形成能力、肿瘤球形成能力、上调癌细胞中癌症干细胞相关的多能性标志物 Sox2 和 Oct4。
Sorafenib (5 μM; 48 h) 可增加 A549 非小细胞肺癌细胞中 ALDH 阳性癌症干细胞的群体。
Sorafenib (5 μM; 48 h) 可显著增强 NCI-H460 非小细胞肺癌细胞的迁移能力。 Sorafenib (5 μM; 48 h) 可通过下调 E-cadherin、上调 N-cadherin、波形蛋白 (vimentin) 及 MMP2,诱导 NCI-H460 非小细胞肺癌 (NSCLC) 细胞发生上皮间质转化,且可通过增强 AKT 磷酸化激活 AKT 通路。
Sorafenib (5 μM; 48 h) 可在 mRNA 和蛋白水平上调 NCI-H460 和 NCI-H1299 非小细胞肺癌细胞中 STMN1、FOXM1 以及 E2F1 的表达。
Western Blot Analysis
| Cell Line: |
MDA-MB-231 |
| Concentration: |
0.01, 0.03, 0.1, 0.3, 1, 3 μM |
| Incubation Time: |
2 h |
| Result: |
Dose-dependently inhibited basal MEK 1/2 phosphorylation in MDA-MB-231 cells with an IC50 of 40 nmol/L. Inhibited ERK 1/2 phosphorylation in MDA-MB-231 cells with an IC50 of 90 nmol/L. Showed no effect on PKB phosphorylation in MDA-MB-231 cells. Completely blocked activation of the MAPK pathway.
|
Cell Proliferation Assay
| Cell Line: |
MDA-MB-231 |
| Concentration: |
0.01-10 μM |
| Incubation Time: |
72 h |
| Result: |
Inhibited MDA-MB-231 cell proliferation with an IC50 of 2600 nmol/L.
|
Western Blot Analysis
| Cell Line: |
HCT8 and HT29 cells |
| Concentration: |
4, 24 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced p21Cip1 protein expression induced by Oxaliplatin or Cisplatin at 4 μM when applied simultaneously. Completely inhibited platinum-induced p21Cip1 expression at 24 μM when applied simultaneously. Reduced cyclin D1 expression enhanced by Oxaliplatin when applied simultaneously. Reduced cdc2 expression enhanced by cisplatin when applied simultaneously. Showed no effect on these protein levels when applied consecutively after platinum treatment. |
Cell Proliferation Assay
| Cell Line: |
HCCLM3, HepG2, MH cells |
| Concentration: |
0, 0.05, 0.1, 1, 5, 10, 20 μmol/L |
| Incubation Time: |
24, 48, 72 h |
| Result: |
Inhibited HCC cell growth in a time- and dose-dependent manner across all three cell lines. Increased inhibition rates with both higher sorafenib concentrations and longer incubation periods. Exhibited the strongest inhibition at 20 μmol/L after 72 h of treatment. |
Western Blot Analysis
| Cell Line: |
HCCLM3, HepG2, MH cells |
| Concentration: |
0, 2, 5, 10, 20 μmol/L |
| Incubation Time: |
2 h (0-20 μmol/L); 2, 6, 12, 24 h (10 μmol/L) |
| Result: |
Inhibited phosphorylation of STAT3 at Y705 and S727, as well as phosphorylation of ERK1/2, in a dose-dependent manner after 2 h of treatment across all three cell lines. Durably inhibited phosphorylation of STAT3 (Y705 and S727) and ERK1/2 for up to 24 h at 10 μmol/L, while total STAT3 protein levels and JAK2 phosphorylation remained unchanged. Inhibited Akt phosphorylation primarily at 2 μmol/L after 2 h and reduced cyclin D1 protein expression, while leaving SHP2 phosphorylation unchanged. |
Western Blot Analysis
| Cell Line: |
A549, NCI-H460, NCI-H1299 cells |
| Concentration: |
5 μM |
| Incubation Time: |
48 h |
| Result: |
Upregulated expression levels of Sox2 and Oct4 in all three NSCLC cell lines compared to untreated controls. Markedly decreased the epithelial marker E-cadherin compared to untreated controls. Correspondingly increased mesenchymal markers N-cadherin, vimentin, and MMP2 compared to untreated controls. Upregulated the expression of phosphorylated AKT in NCI-H460 cells compared to untreated controls. Showed no obvious effect on phosphorylated JNK expression compared to untreated controls in NCI-H460 cells. Showed an increase in phosphorylated ERK expression compared to untreated controls in NCI-H460 cells.
|
Cell Migration Assay
| Cell Line: |
NCI-H460 cells |
| Concentration: |
5 μM |
| Incubation Time: |
48 h |
| Result: |
Resulted in the strongest enhancement of cell migration. Showed a higher CI (the capacity for cell migration) slope indicating faster migration velocity compared to DMSO-treated controls. |
Western Blot Analysis
| Cell Line: |
NCI-H460, NCI-H1299 cells |
| Concentration: |
5 μM |
| Incubation Time: |
48 h |
| Result: |
Upregulated STMN1, FOXM1, and E2F1 protein expression in both cell lines compared to untreated controls. |
|
体内研究 (In Vivo) |
Sorafenib (7.5-60 mg/kg;口服;每日给药;连续 5 天或 9天) 在小鼠乳腺癌、结肠癌和非小细胞肺癌异种移植模型中,抑制肿瘤生长,抑制 RAF/MEK/ERK 信号通路,并减少血管生成,且未观察到毒性。 Sorafenib (30 mg/kg;灌胃;每日 1 次;从第 17 天到第 38 天) 在原位大鼠 MH 模型中强效抑制肝细胞癌的肿瘤生长和转移,同时诱导肿瘤细胞凋亡并抑制 STAT3、Akt 及 ERK 的磷酸化。 Sorafenib (10 mg/kg;口服;每日一次;连续 2 周) 在 DENA 诱导的白化大鼠肝细胞癌模型中表现出抗肿瘤活性。 Sorafenib (4 mg/kg;腹腔注射;每周 2 次;持续 4 周) 联合瘤内注射 siTUC338,可通过上调 RASAL1 显著降低小鼠 HepG2/Sor 异种移植瘤的肿瘤体积。
| Animal Model: |
Female NCr-nu/nu mice subcutaneously injected with MDA-MB-231 cells |
| Dosage: |
7.5; 15; 30; 60 mg/kg |
| Administration: |
p.o.; daily for 5 or 9 days |
| Result: |
Produced a 42% reduction in mean tumor weight after 9 days at 30 mg/kg. Inhibited microvessel area (MVA) and microvessel density (MVD) in tumors, induced extensive tumor necrosis, reduced phosphorylated ERK 1/2 (pERK) levels, and decreased Ki-67 staining at 30 or 60 mg/kg daily for 5 days. Caused no toxicity in treated group. |
| Animal Model: |
Female NCr-nu/nu mice subcutaneously injected with Colo-205, HT-29, and DLD-1 cells |
| Dosage: |
7.5; 15; 30; 60 mg/kg |
| Administration: |
p.o.; daily for 5 or 9 days |
| Result: |
Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily for 9 days. Reduced MVA to ~0.4% and MVD to ~80/mm2 at 30 mg/kg daily for 5 days, and reduced MVA to ~0.2% and MVD to ~50/mm2 at 60 mg/kg daily for 5 days relative to vehicle controls. Detected no reduction in pERK levels at 30 or 60 mg/kg daily for 5 days. Caused no toxicity in any treated group.\n Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily for 9 days. Inhibited MVA and MVD in tumors by 50 to 80%, reduced pERK levels, and inhibited MEK 1/2 phosphorylation at 30 or 60 mg/kg daily for 5 days. Caused no toxicity in any treated group. |
| Animal Model: |
Female NCr-nu/nu mice subcutaneously injected with NCI-H460, and A549 cells |
| Dosage: |
7.5; 15; 30; 60 mg/kg |
| Administration: |
p.o.; daily; 9 days |
| Result: |
Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily. Caused no toxicity in any treated group. |
| Animal Model: |
Male ACI rats (200-220 g) orthotopic implantated with Morris Hepatoma (MH) fragments |
| Dosage: |
30 mg/kg |
| Administration: |
i.g.; once daily from day 17 to day 38 |
| Result: |
Reduced mean tumor volume to 351.26 mm3 in early treatment group and 2248.33 mm3 in late treatment group. Prevented lung, lymph node metastasis, peritoneal seeding, and ascites in 10/10 rats in early treatment group, and lymph node metastasis, peritoneal seeding, and ascites in 10/10 rats in late treatment group. Induced tumor cell apoptosis with an apoptosis index of 0.909. Reduced phosphorylation of STAT3 (Y705 and S727), Akt, and ERK in tumor tissue. Decreased cyclin D1 expression. Did not affect STAT3 mRNA levels, JAK2 phosphorylation, or SHP2 phosphorylation in tumor tissue. |
| Animal Model: |
Male albino rats (100-120 g) with Diethyl Nitrosamin (DENA)-induced hepatocellular carcinoma) |
| Dosage: |
10 mg/kg |
| Administration: |
p.o.; daily; 2 weeks |
| Result: |
Improved survival rate to 83.3%. Significantly decreased liver index below normal control group level. Reduced hepatocellular foci size by 34.8% compared to the DENA-only group. Lowered total hepatic foci count to 10 compared to 18 in the DENA-only group. Decreased cyclin D1 and β-catenin gene expression. Reduced liver Bcl-2 protein and liver glutathione (GSH) levels. |
| Animal Model: |
Male nude mice (4-6 weeks, 18-20 g) subcutaneously injected with HepG2/Sor cells |
| Dosage: |
4 mg/kg |
| Administration: |
i.p.; twice a week; 4 weeks |
| Result: |
Achieved statistically significantly lower mean tumor volume compared to sorafenib combined with saline or siNC. Significantly downregulated TUC338 expression in tumor tissue relative to control groups. Significantly upregulated RASAL1 mRNA and protein levels in tumor tissue relative to control groups. |
|
| 性状 |
固体 |
| 颜色 |
White to off-white |